3 results
Primary objectives To demonstrate the non-inferiority of CHF 5993 pMDI versus fixed combination of fluticasone furoate/vilanterol plus tiotropium in terms of quality of life (change from baseline in the St. George*s Respiratory Questionnaire [SGRQ]…
Primary ObjectiveThe primary efficacy objective of the study is to assess the effect of garetosmab (10 mg/kg) versus placebo on the formation of new HO lesions from baseline to week 56, as determined by low dose CT.The primary safety objective of…
Primary Objectives:• Determine the safety and tolerability of CC-122 administered in combination with obinutuzumab.• Determine the non-tolerated dose (NTD), maximum tolerated dose (MTD), and recommended Phase 2 dose (RP2D) of CC-122 administered in…